We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
BaroFold Grants Protein Technology Research License to Genentech
News

BaroFold Grants Protein Technology Research License to Genentech

BaroFold Grants Protein Technology Research License to Genentech
News

BaroFold Grants Protein Technology Research License to Genentech

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "BaroFold Grants Protein Technology Research License to Genentech "

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

BaroFold, Inc. has announced the granting of a research license to Genentech, Inc. for BaroFold's proprietary PreEMT™ high pressure technology for solubilizing, disaggregating and refolding proteins under a previously executed service and license agreement.

The license agreement enables Genentech to utilize BaroFold's patented technology and instrumentation for research, and grants Genentech an option to trigger a commercial license.

Genentech joins several other biotechnology firms and pharmaceutical corporations who have collaborated with BaroFold to refold and produce proteins.

"We are pleased to be working with Genentech, a leader and pioneer in the field of therapeutic proteins," said Lyndal Hesterberg, President and CEO of BaroFold Inc.

"Our team has now delivered useful quantities of over 80 challenging proteins through its collaborations with academics and biologics industry scientists."

"We hope to support future development of important therapeutic biologics programs at Genentech."

Advertisement